Compare FELE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FELE | TNGX |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.1B |
| IPO Year | 1995 | 2020 |
| Metric | FELE | TNGX |
|---|---|---|
| Price | $97.15 | $23.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $103.50 | $21.78 |
| AVG Volume (30 Days) | 157.2K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $2,131,250,000.00 | $62,384,000.00 |
| Revenue This Year | $6.84 | N/A |
| Revenue Next Year | $3.43 | N/A |
| P/E Ratio | $125.95 | ★ N/A |
| Revenue Growth | 5.44 | ★ 48.29 |
| 52 Week Low | $89.54 | $6.69 |
| 52 Week High | $115.82 | $34.39 |
| Indicator | FELE | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 46.23 |
| Support Level | $95.08 | $19.74 |
| Resistance Level | $101.78 | $26.38 |
| Average True Range (ATR) | 1.65 | 1.40 |
| MACD | -0.35 | 0.23 |
| Stochastic Oscillator | 6.88 | 42.03 |
Franklin Electric Co Inc designs, manufactures, and distributes water and fuel pumping systems, composed of submersible motors, pumps, electronic controls, water treatment systems, and related parts and equipment. It has three segments; The Water Systems segment designs, manufactures and sells motors, pumps, drives, electronic controls, monitoring devices, and related parts and equipment for use in groundwater, water transfer, and wastewater, The Energy Systems segment designs, manufactures and sells pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment for use in fueling system applications and the Distribution segment sells and provides presale support and specifications to the installing contractors.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.